Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment

Rhea-AI Summary

Autonomix Medical (NASDAQ: AMIX) participated in a Virtual Investor CEO Connect segment on Dec 23, 2025. CEO Brad Hauser outlined two strategic priorities:

• Strengthening intellectual property to protect and expand the company’s platform.
• Evaluating multi‑indication opportunities beyond pancreatic cancer, including potential applications in cardiovascular, pulmonary, and interventional pain management.

The CEO segment is available online for investors to review.

Market Reality Check

$0.5122 Last Close

Volume Volume 105,407 is about 0.34x the 20-day average of 306,891, indicating subdued trading ahead of this update. low

Technical Shares trade below the 200-day MA, with price at $0.6447 versus MA200 at $1.37, reflecting a longer-term downtrend.

Peers on Argus 3 Up

Peers show mixed action: BMRA up 2.6%, MOVE up 4.3%, while HSDT is down 5.05%. With AMIX modestly higher and sector moves not clearly synchronized, today’s news appears more company-specific than sector-driven.

Common Catalyst Some peers, such as BMRA, also have product- and reimbursement-related news, but there is no broad, shared catalyst across medical device names.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 18	Conference poster selection	Positive	+4.6%	ASCO GI 2026 poster acceptance for pancreatic cancer pain mitigation study.
Nov 26	CEO communication	Positive	+10.2%	CEO Corner update on IP protection and multi-indication expansion strategy.
Nov 18	Private placement	Negative	-17.4%	At‑the‑market priced private placement with new shares and Series C warrants.
Nov 17	Clinical data update	Positive	+58.2%	Post‑hoc PoC 1 analysis showing sustained quality‑of‑life gains in pancreatic pain.
Oct 24	Conference presentations	Positive	+0.0%	TCT podium presentations on early proof‑of‑concept pancreatic pain trial results.

Pattern Detected

AMIX often reacts positively to clinical and visibility milestones, while financing events like private placements have coincided with sharp declines.

Recent Company History

Over the past few months, Autonomix has highlighted clinical progress and growing visibility in pancreatic cancer pain, including positive proof-of-concept data and podium or poster selections at major meetings like TCT 2025 and ASCO GI 2026. Alongside this, the company executed a $5.0 million private placement and related warrant registration steps. Prior CEO communication also emphasized IP protection and platform expansion beyond pancreatic cancer, which mirrors the strategic themes highlighted in today’s Virtual Investor segment.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-11-26

$7.7 million registered capacity

An effective S-3 registration covers 13,504,998 warrant shares for resale tied to a PIPE, with potential gross proceeds of up to $7.7 million to Autonomix if the common warrants are exercised in cash. Full exercise would significantly increase the share count, as highlighted in the filing, implying meaningful dilution risk alongside added capital flexibility.

Market Pulse Summary

The stock moved -7.0% in the session following this news. A negative reaction despite management reiterating its IP and multi‑indication strategy would contrast with several past positive responses to clinical and visibility updates, though it would resemble the sharp decline of 17.38% seen on the November private placement. The existing S-3 resale shelf for 13,504,998 warrant shares and potential cash proceeds of $7.7 million underscore ongoing dilution risk that could weigh on sentiment around strategic communications.

Key Terms

pancreatic cancer medical

"evaluating opportunities beyond pancreatic cancer, including potential applications"

Pancreatic cancer is a disease in which cells in the pancreas grow out of control, forming a tumor that disrupts the organ’s role in digestion and blood-sugar regulation; because it often spreads early and is hard to detect, outcomes tend to be poor. For investors, it matters because diagnosis rates, treatment advances, drug approvals, and clinical trial results can strongly affect the value of biotech and healthcare companies—think of a breakthrough therapy as a new part that could fix a failing engine and reshape market expectations.

cardiovascular medical

"including potential applications in cardiovascular, pulmonary and interventional pain"

Relating to the heart and the network of blood vessels that pump and carry blood through the body — like the body’s engine and plumbing working together. Investors pay attention because conditions, treatments, devices, and drugs tied to this system drive large health care spending, regulatory reviews, and market demand; breakthroughs, safety issues, or trial results can quickly change a company’s revenue prospects and stock value.

pulmonary medical

"including potential applications in cardiovascular, pulmonary and interventional pain"

Relating to the lungs and the system that moves air in and out of the body; pulmonary describes anything involving breathing, oxygen exchange, or lung tissue. Investors care because pulmonary problems and treatments affect demand for medical services, drug development, equipment, and worker productivity—similar to how a clogged air filter reduces engine performance, impaired lungs can slow economic activity for healthcare providers, insurers, and companies developing therapies or devices.

interventional pain management medical

"pulmonary and interventional pain management areas."

Interventional pain management is a medical field that treats chronic pain using targeted, often minimally invasive procedures—such as injections, nerve blocks, small surgical techniques, or implantable devices—rather than long-term pills or major surgery. Investors care because these procedures drive demand for specialized devices, clinics and trained providers, are sensitive to regulatory approvals and insurance reimbursement, and can meaningfully affect revenues and growth prospects in healthcare and medical-device markets.

AI-generated analysis. Not financial advice.

Access the segment here

THE WOODLANDS, TX, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it recently participated in a Virtual Investor CEO Connect segment.

As part of the segment, Brad Hauser, CEO of Autonomix, outlined two key priorities shaping the Company’s trajectory: strengthening its platform through intellectual property protection and evaluating opportunities beyond pancreatic cancer, including potential applications in cardiovascular, pulmonary and interventional pain management areas.

The Virtual Investor CEO Connect segment is now available here.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Investor and Media Contact

JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com

FAQ

What did Autonomix (AMIX) announce in the Dec 23, 2025 CEO Connect segment?

CEO Brad Hauser said the company is prioritizing IP protection and exploring applications beyond pancreatic cancer in cardiovascular, pulmonary, and interventional pain areas.

How does Autonomix plan to strengthen its platform according to the AMIX CEO presentation?

The company plans to focus on expanding and protecting intellectual property around its nerve‑targeted treatment platform.

Will Autonomix (AMIX) pursue indications beyond pancreatic cancer and which ones were named?

Yes; the CEO identified potential opportunities in cardiovascular, pulmonary, and interventional pain management.

Where can investors watch the Autonomix (AMIX) Virtual Investor CEO Connect segment from Dec 23, 2025?

The CEO Connect segment is available online via the company’s published Virtual Investor CEO Connect link.

Does the Dec 23, 2025 AMIX update include financial guidance or clinical results?

No; the segment focused on strategic priorities (IP and indication expansion) and did not present financial guidance or clinical data.